Cargando…

Lutetium-177-PSMA-617: A Vision of the Future

In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[(177)Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandran, Elias, Figg, William D., Madan, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890398/ https://www.ncbi.nlm.nih.gov/pubmed/35220877 http://dx.doi.org/10.1080/15384047.2022.2037985

Ejemplares similares

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance
por: Huang, Phoebe A., et al.
Publicado: (2018)

Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics
por: Hall, O. Morgan, et al.
Publicado: (2018)

Safety and Efficacy of (177)Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing (223)Radium-Dichloride
por: Baumgarten, Justus, et al.
Publicado: (2022)

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT
por: Handy, Whitney F., et al.
Publicado: (2020)

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
por: Sutherland, Duncan E. K., et al.
Publicado: (2023)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Minimal invasive brain surgery for epilepsy; can it be the future?
por: Mustafa, Mohamed, et al.
Publicado: (2022)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

First communication on the efficacy of combined (177)Lutetium-PSMA with immunotherapy outside prostate cancer
por: Digklia, Antonia, et al.
Publicado: (2022)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Predicting the neuro‐cardio‐haemodynamic outcomes of sepsis and its pharmacological interventions: Get to the future through numerical equations
por: Sutanto, Henry, et al.
Publicado: (2021)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

PSMA-617 inhibits proliferation and potentiates the (177)Lu-PSMA-617-induced death of human prostate cancer cells
por: Zhao, Yi, et al.
Publicado: (2023)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

Journal Club Review of “Avacopan for the Treatment of ANCA‐Associated Vasculitis”
por: Soulsby, William Daniel
Publicado: (2022)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
por: Tiwari, Vivekanand, et al.
Publicado: (2021)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

A novel mechanism of rotavirus infection involving purinergic signaling
por: Morales-Soto, Wilmarie, et al.
Publicado: (2021)

The benefit of considering others in individual health decisions
por: Sievert, Elisabeth D. C.
Publicado: (2023)

Intracerebral haemorrhage on the acute stroke unit
por: Edwards, M. D., et al.
Publicado: (2019)

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Neurotoxicity of novel cancer immunotherapies
por: Willis, M. D., et al.
Publicado: (2019)

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis
por: Willis, M. D., et al.
Publicado: (2017)

Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation
por: McLauchlan, D., et al.
Publicado: (2016)

B cell treatments for multiple sclerosis
por: McLauchlan, D., et al.
Publicado: (2017)

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis
por: McLauchlan, D., et al.
Publicado: (2020)

Imaging in the diagnosis of progressive supranuclear palsy
por: Smith, Matthew D., et al.
Publicado: (2018)

Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment
por: McLauchlan, D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mm8332kc5fo5gv7iod5456kes0